Gardiner Harris’s investigation of Johnson & Johnson explores the many ways corporate greed and weak regulations fail to ...

Eating Protein Saves Lives, Inc. announces the release of EAT!: A Guide to Radiant Recovery Using Food and Amino Acids to Repair the Addicted Brain and Reduce Cravings, a groundbreaking new book ...

Veravas, a leader in clinical diagnostics, today announced the general commercial availability of VeraBINDtm Tau, the first blood-based test designed to aid in the detection of Alzheimer's disease (AD ...

The primary objective is to assess the efficacy of Cobenfy as an adjunctive treatment to one of several atypical antipsychotics compared to placebo with an atypical antipsychotic as measured by ...

The Phase 3 test evaluated the drug, Cobenfy, as an adjunct to atypical antipsychotics in adults whose schizophrenia symptoms were inadequately controlled by these standard-of-care drugs.

Bristol Myers Squibb's Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with ...

Management of adverse events is a major concern of clinicians who use antipsychotic drugs. The incidence of motor side effects is dose dependent. Atypical antipsychotic drugs are less likely to ...

Cobenfy as an adjunctive treatment to atypical antipsychotics failed to show superior efficacy versus placebo with atypicals when used in patients with inadequately controlled schizophrenia ...